<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433523</url>
  </required_header>
  <id_info>
    <org_study_id>MT-04</org_study_id>
    <secondary_id>2010-018621-19</secondary_id>
    <nct_id>NCT01433523</nct_id>
  </id_info>
  <brief_title>House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma</brief_title>
  <acronym>MITRA</acronym>
  <official_title>Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACM Pivotal Global Central Laboratory</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate if treatment with house dust mite allergen
      immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust
      mite induced asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first moderate or severe asthma exacerbation after ICS reduction</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in immunological parameters (IgE, IgG4)</measure>
    <time_frame>Measured at the end of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe asthma exacerbation after ICS reduction</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of asthma exacerbations following ICS reduction</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average overall symptom score.</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom free days</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment emergent AEs</measure>
    <time_frame>At end of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">834</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK HDM AIT 6 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK HDM AIT 12 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK HDM AIT Placebo</intervention_name>
    <description>Oral lyophilisate, Placebo, to be administered sublingually once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK HDM AIT 6 DU</intervention_name>
    <description>Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.</description>
    <arm_group_label>ALK HDM AIT 6 DU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK HDM AIT 12 DU</intervention_name>
    <description>Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.</description>
    <arm_group_label>ALK HDM AIT 12 DU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  A clinical relevant history consistent with house dust mite induced asthma of at least
             1 year prior to trial entry.

          -  Use of an appropriate amount of inhaled corticosteroid for the control of asthma
             symptoms.

          -  Documented reversible airway obstruction.

          -  Suitable level of asthma control.

          -  FEV1 ≥ 70% of predicted value.

          -  Positive Skin Prick Test response to Der pte and/or Der far.

          -  Positive specific IgE against Der pte and/or Der far (≥ IgE Class 2; ≥ 0.70 KU/L).

        Key Exclusion Criteria:

          -  A clinical history of persistent allergic asthma or rhinitis caused by an allergen to
             which the subject is regularly exposed and sensitised (except house dust mites).

          -  A clinical history of intermittent allergic asthma or rhinitis if the seasonal
             allergen is causing symptoms in the period from October to March.

          -  Any clinically relevant chronic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Virchow, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. fof Pneumology, University Clinic Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock, Abteilung für Pneumologie Zentrum für Innere Medizin, Ernst Heydemann Strasse 6</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDM</keyword>
  <keyword>AIT</keyword>
  <keyword>asthma</keyword>
  <keyword>asthma exacerbation</keyword>
  <keyword>House dust mite induced asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

